한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

First, the intensification of market competition is one of the important factors leading to these changes. With the continuous advancement of science and technology and the rise of emerging markets, competition in the pharmaceutical industry has become increasingly fierce. Many small innovative pharmaceutical companies have made breakthrough progress in specific fields with their unique R&D technology and flexible operating models, which has brought tremendous pressure to traditional multinational pharmaceutical companies. In order to cope with the competition, multinational pharmaceutical companies have to readjust their strategic layout, optimize resource allocation by laying off employees and selling some businesses, and focus on developing core products and markets.

Secondly, changes in the policy environment have also had a profound impact on multinational pharmaceutical companies. In order to control medical costs, governments have strengthened supervision and regulation of drug prices. This has squeezed the profit margins of multinational pharmaceutical companies in some markets, forcing them to take measures to reduce costs in order to maintain their profitability. For example, some countries have adjusted the protection period of patented drugs, speeding up the launch of generic drugs, and further impacting the market share of multinational pharmaceutical companies.

In addition, the rising cost of R&D is also a severe challenge faced by multinational pharmaceutical companies. Developing a new drug requires a lot of money, time and manpower, and the success rate is not high. With the increasing complexity of science and technology and the increasingly stringent requirements of clinical trials, R&D costs continue to increase. In this case, if the R&D project fails to achieve the expected results, the company may face huge economic losses. Therefore, multinational pharmaceutical companies need to be more cautious in selecting R&D projects and reduce risks by optimizing R&D processes and cooperation models.

So, how do these changes relate to the international express delivery industry? On the one hand, layoffs and business adjustments by multinational pharmaceutical companies may lead to changes in the production and transportation volume of drugs, thereby affecting the business volume of international express delivery. For example, when a multinational pharmaceutical company closes a production base or reduces the production of a certain drug, the transportation demand for related raw materials and finished products will decrease, which may have a certain impact on international express delivery companies that rely on drug transportation business.

On the other hand, when selling their Chinese subsidiaries, multinational pharmaceutical companies may need to transport a large amount of documents, information and equipment. This is not only a business opportunity for international express delivery, but also places higher demands on service quality and transportation efficiency. If international express delivery companies can provide professional, efficient and safe transportation solutions, they may win the business of these multinational pharmaceutical companies and expand their market share.

At the same time, multinational pharmaceutical companies may increase their investment in emerging markets in the process of adjusting their strategic layout. These emerging markets often have a rapid growth in demand for drugs, but their logistics infrastructure is relatively weak. International express companies can seize this opportunity to cooperate with multinational pharmaceutical companies to jointly improve the logistics network, improve the efficiency and coverage of drug distribution, and provide better medical services for local patients.

In addition, as multinational pharmaceutical companies pay more and more attention to digital transformation to improve operational efficiency and reduce costs, the international express delivery industry also needs to improve its information level accordingly. By establishing a digital logistics platform, real-time tracking and sharing of logistics information can be achieved, the transparency and controllability of the supply chain can be improved, and the precision and personalized needs of multinational pharmaceutical companies for logistics services can be met.

In summary, a series of changes in multinational pharmaceutical companies are closely related to the international express delivery industry. The international express delivery industry needs to pay close attention to the dynamics of multinational pharmaceutical companies and continuously optimize its own services and operating models to adapt to market changes and demands and achieve sustainable development.